Explained: A brief look into AlphaFold 2
The year 2021 has been a wild ride for structural biologists, with the advent of AlphaFold2,...
BioStrand Omics Analysis Blog:
Drug Development (2)
AI-powered genomics to advance precision medicine
Sir William Osler, often called the father of modern medicine, was among the first to articulate a ...
AI, NLP and the ROI of drug development
The out-of-pocket R&D costs of developing a single drug, whether successfully launched or not, are...
Accelerating pharma R&D and innovation through technology partnerships
Biopharmas are increasingly turning to alliances & partnerships to drive external innovation....
Functional multiomics and antibody discovery
Genomics is the forerunner of all omics technologies, first introduced in 1987 as the name of a new...
Computational Antibody Design: The Future Of Antibody Discovery
In 2021, the FDA approved the 100th monoclonal antibody product, marking a significant milestone...
Improving Drug Safety with Adverse Event Detection Using NLP
It is estimated that Adverse Events (AEs) are likely one of the 10 leading causes of death and...
A Hybrid Approach to NLP in Drug Discovery
Artificial Intelligence-powered technologies like NLP are becoming critical to the pharmaceutical...
AI in early phase drug development
AI technologies are currently the most disruptive trend in the pharmaceutical industry. Over the...
AI in drug development - towards fully autonomous drug discovery
In our previous blog, we noted how the increasing utilization of AI across different phases of the...